Want to join the conversation?
$REGN, which competes with $AMGN & Novartis AG, said that 4Q15 EYLEA US net sales grew 44% YoverY to $746MM. The market share of treated eyes for EYLEA and DME is roughly double that of ranibizumab and similar to that for off-label bevacizumab. Praluent net sales were $7MM, which understates actual physician and patient demand.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.